PL2614835T3 - Szczepienie wieloma kladami wirusa grypy A H5 - Google Patents

Szczepienie wieloma kladami wirusa grypy A H5

Info

Publication number
PL2614835T3
PL2614835T3 PL12198671T PL12198671T PL2614835T3 PL 2614835 T3 PL2614835 T3 PL 2614835T3 PL 12198671 T PL12198671 T PL 12198671T PL 12198671 T PL12198671 T PL 12198671T PL 2614835 T3 PL2614835 T3 PL 2614835T3
Authority
PL
Poland
Prior art keywords
vaccination
influenza
virus
multiple clades
clades
Prior art date
Application number
PL12198671T
Other languages
English (en)
Inventor
Audino Podda
Rino Rappuoli
Original Assignee
Seqirus UK Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2614835(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seqirus UK Limited filed Critical Seqirus UK Limited
Publication of PL2614835T3 publication Critical patent/PL2614835T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12198671T 2007-11-26 2008-11-25 Szczepienie wieloma kladami wirusa grypy A H5 PL2614835T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US433407P 2007-11-26 2007-11-26
GBGB0810305.3A GB0810305D0 (en) 2008-06-05 2008-06-05 Influenza vaccination
PCT/IB2008/003580 WO2009068992A1 (en) 2007-11-26 2008-11-25 Vaccination with multiple clades of h5 influenza a virus
EP08854338.4A EP2211901B2 (en) 2007-11-26 2008-11-25 Vaccination with multiple clades of h5 influenza a virus
EP12198671.5A EP2614835B1 (en) 2007-11-26 2008-11-25 Vaccination with multiple clades of H5 influenza A virus

Publications (1)

Publication Number Publication Date
PL2614835T3 true PL2614835T3 (pl) 2020-03-31

Family

ID=39638239

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12198671T PL2614835T3 (pl) 2007-11-26 2008-11-25 Szczepienie wieloma kladami wirusa grypy A H5
PL08854338.4T PL2211901T5 (pl) 2007-11-26 2008-11-25 Szczepienie wieloma kladami wirusa grypy H5

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08854338.4T PL2211901T5 (pl) 2007-11-26 2008-11-25 Szczepienie wieloma kladami wirusa grypy H5

Country Status (17)

Country Link
US (1) US9669088B2 (pl)
EP (2) EP2614835B1 (pl)
JP (3) JP5957176B2 (pl)
KR (2) KR20160079140A (pl)
CN (1) CN101969995A (pl)
AU (2) AU2008331238B2 (pl)
CA (1) CA2706619C (pl)
CY (1) CY1114762T1 (pl)
DK (2) DK2211901T3 (pl)
ES (2) ES2417495T5 (pl)
GB (1) GB0810305D0 (pl)
HR (1) HRP20130634T1 (pl)
NZ (1) NZ585674A (pl)
PL (2) PL2614835T3 (pl)
PT (2) PT2614835T (pl)
SI (1) SI2211901T1 (pl)
WO (1) WO2009068992A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) * 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
WO2010103022A2 (en) * 2009-03-12 2010-09-16 Sanofi Pasteur Oil-in-water adjuvanted influenza vaccine
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US8673314B2 (en) * 2009-05-26 2014-03-18 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP2013520172A (ja) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ インフルエンザウイルス疾患の予防及び治療で用いるためのワクチン
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
ES2739711T3 (es) 2010-07-22 2020-02-03 John W Schrader Anticuerpo de protección cruzada contra la infección por el virus de la gripe
US10485863B2 (en) * 2010-07-23 2019-11-26 Novavax AB Influenza vaccine
EP2636735B1 (en) * 2010-10-15 2019-12-04 Tokyo Metropolitan Institute of Medical Science Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9504741B2 (en) 2011-11-23 2016-11-29 Vacdiagn Biotechnology Co., Ltd. Immune methods against influenza viruses and combinatorial vaccines thereof
EP2934581B1 (en) 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CN105288609A (zh) * 2015-10-16 2016-02-03 天津瑞普生物技术股份有限公司 一种基于杆状病毒表达系统的禽流感病毒疫苗制备方法
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019035972A1 (en) * 2017-08-16 2019-02-21 Georgia State University Research Foundation, Inc. SEQUENTIAL IMMUNIZATIONS WITH HIV-1 ENV VIRUS TYPE PARTICLES
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
MX2019014943A (es) 2018-12-12 2020-08-06 Cambridge Tech Llc Vacuna universal contra la gripe.
CN113842455B (zh) * 2021-08-27 2022-05-13 北京康乐卫士生物技术股份有限公司 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060082A (en) 1976-08-16 1977-11-29 Mpl, Inc. Dual-ingredient medication dispenser
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2131070T3 (es) 1991-03-01 1999-07-16 Minnesota Mining & Mfg 1h-imidazo(4,5-c)quinolin-4-aminas sustituidas en posicion 1 y sustituidas en posicion 2.
JPH0614756Y2 (ja) 1991-06-26 1994-04-20 株式会社アルテ 組み立て式の２室式容器兼用注射器
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2180965C (en) 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5496284A (en) 1994-09-27 1996-03-05 Waldenburg; Ottfried Dual-chamber syringe & method
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
AU3186297A (en) 1996-07-05 1998-02-02 Debiotech S.A. Dual-chamber syringe for mixing two substances prior to injection
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1998046262A1 (en) 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
AU9785598A (en) 1997-10-03 1999-04-27 Texas Pharmaceuticals, Inc. Improved dual chamber syringe apparatus
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6630161B1 (en) 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE19835749C1 (de) 1998-08-07 2000-02-03 Dieter Perthes Fertig-Spritze für nicht-stabile Arzneimittel
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
DE60039198D1 (de) 1999-03-26 2008-07-24 Vical Inc Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
MXPA02003069A (es) 1999-09-24 2002-09-30 Smithkline Beecham Biolog Vacuna intranasal contra el virus de la influenza..
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
PL354997A1 (pl) 1999-09-25 2004-03-22 University Of Iowa Research Foundation Immunostymulujące kwasy nukleinowe
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1311288A1 (en) 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
US6951754B2 (en) 2000-04-28 2005-10-04 St. Jude Children's Research Hospital DNA transfection system for the generation of infectious influenza virus
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
ATE448226T1 (de) 2000-09-01 2009-11-15 Novartis Vaccines & Diagnostic Aza heterocyclische derivate und ihre therapeutische verwendung
KR100732206B1 (ko) 2000-09-11 2007-06-27 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 티로신 키나제 억제제로서의 퀴놀리논 유도체
CA2423487C (en) 2000-09-26 2015-12-15 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
AR032575A1 (es) 2001-02-23 2003-11-12 Smithkline Beecham Biolog Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna
ATE489968T1 (de) 2001-03-09 2010-12-15 Id Biomedical Corp Quebec Proteosom-liposaccharid-vakzine-adjuvans
EP1372528B1 (en) 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
FR2832423B1 (fr) 2001-11-22 2004-10-08 Vivalis Systeme d'expression de proteines exogenes dans un systeme aviaire
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
DK1499311T3 (da) 2002-03-29 2010-03-08 Novartis Vaccines & Diagnostic Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
EP1537099B1 (en) 2002-08-23 2010-08-11 Novartis Vaccines and Diagnostics, Inc. Pyrrole based inhibitors of glycogen synthase kinase 3
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
CN1933862A (zh) 2004-03-23 2007-03-21 尼普洛株式会社 预充式注射器
EP1732384A4 (en) 2004-03-31 2008-04-23 Univ New York State Res Found NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES
BRPI0509606B1 (pt) 2004-04-05 2019-01-15 Pah Usa 15 Llc emulsões de óleo-em-água microfluidizadas e composições para vacinas
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
ATE488248T1 (de) 2004-09-09 2010-12-15 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
TWI365074B (en) 2004-10-07 2012-06-01 Wyeth Corp Multivalent avian influenza vaccines
CA2585672A1 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
BRPI0518568A2 (pt) 2004-12-24 2008-11-25 Solvay Pharm Bv mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico
PE20061428A1 (es) † 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2613284A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing negative-sense viral rna in canine cells
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
SI1951296T2 (sl) 2005-11-01 2014-09-30 Novartis Vaccines And Diagnostics Gmbh Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom
JP2009514850A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
US20100158943A1 (en) 2005-11-04 2010-06-24 Novartis Vaccines And Diagnostics Srl Administration routes for priming/boosting with influenza vaccines
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
US20080014217A1 (en) * 2006-07-17 2008-01-17 Emmanuel Jules Hanon Influenza vaccine
CL2008000747A1 (es) 2007-03-16 2008-04-25 Wyeth Corp Composicion de vacuna que comprende una primera y una segunda cepa inactivada del virus de la influenza aviar; metodo para vacunar un ave.

Also Published As

Publication number Publication date
JP2014159454A (ja) 2014-09-04
HK1146577A1 (en) 2011-06-24
DK2211901T3 (da) 2013-07-08
KR20160079140A (ko) 2016-07-05
ES2417495T5 (es) 2023-10-06
EP2614835A1 (en) 2013-07-17
AU2014203436B2 (en) 2016-11-17
CN101969995A (zh) 2011-02-09
SI2211901T1 (sl) 2013-08-30
KR20100108527A (ko) 2010-10-07
HRP20130634T1 (hr) 2013-08-31
AU2008331238B2 (en) 2014-03-27
US20110189230A1 (en) 2011-08-04
PL2211901T5 (pl) 2023-11-06
CY1114762T1 (el) 2016-12-14
ES2755895T3 (es) 2020-04-24
JP2016155867A (ja) 2016-09-01
GB0810305D0 (en) 2008-07-09
PT2211901E (pt) 2013-07-10
ES2417495T3 (es) 2013-08-08
US9669088B2 (en) 2017-06-06
EP2211901A1 (en) 2010-08-04
JP5957176B2 (ja) 2016-07-27
WO2009068992A1 (en) 2009-06-04
PL2211901T3 (pl) 2013-11-29
WO2009068992A8 (en) 2013-09-12
AU2014203436A1 (en) 2014-07-10
EP2211901B1 (en) 2013-05-01
JP2011504486A (ja) 2011-02-10
EP2211901B2 (en) 2023-04-26
NZ585674A (en) 2013-01-25
EP2614835B1 (en) 2019-08-21
CA2706619C (en) 2015-05-19
DK2614835T3 (da) 2019-11-25
AU2008331238A1 (en) 2009-06-04
CA2706619A1 (en) 2009-06-04
PT2614835T (pt) 2019-11-27

Similar Documents

Publication Publication Date Title
SI2211901T1 (sl) Cepljenje z več gručami virusa gripe H5 A
PL2185191T3 (pl) Szczepionki przeciwko grypie o małej zawartości dodatków
IL196024A0 (en) Influenza vaccine
SMT201800178T1 (it) Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA200809056B (en) Influenza virus vaccine
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
GB0918679D0 (en) Influenza vaccine
PT2422810E (pt) Vacina da gripe
ZA201100962B (en) Influenza vaccines
EP2368899B8 (en) Avian influenza vaccine
EP2496255A4 (en) ADJUVATED INFLUENZA VACCINE IN NANOPARTICLE FORM
IL202670A0 (en) Intradermal influenza vaccine
EP2240199A4 (en) INFLUENZA VACCINES
ZA201005238B (en) Canine influenza vaccines
ZA200900062B (en) Influenza vaccine
GB0723987D0 (en) Influenza vaccine reagents
GB0618195D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
HK1127296A (en) Influenza virus vaccine
HK1160799A (en) Influenza vaccines with reduced amounts of squalene